A5068285758- Acute Myeloid Leukemia Research
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- Ferroptosis and cancer prognosis
- MicroRNA in disease regulation
- RNA modifications and cancer
- Protein Degradation and Inhibitors
- Cancer, Hypoxia, and Metabolism
- Virus-based gene therapy research
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Adrenal and Paraganglionic Tumors
- RNA Research and Splicing
- Circular RNAs in diseases
- Chromatin Remodeling and Cancer
- CAR-T cell therapy research
- Beetle Biology and Toxicology Studies
- Synthetic Organic Chemistry Methods
The University of Sydney
2016-2025
Children's Cancer Institute Australia
2019-2020
Cancer Institute of New South Wales
2020
UNSW Sydney
2020
Northern Sydney Local Health District
2016-2019
Royal North Shore Hospital
2016-2019
Abstract The overall prognosis of acute myeloid leukemia (AML) remains dismal, largely because the inability current therapies to kill stem cells (LSCs) with intrinsic resistance. Loss stress sensor growth arrest and DNA damage-inducible 45 alpha (GADD45A) is implicated in poor clinical outcomes, but its role LSCs AML pathogenesis unknown. Here, we define GADD45A as a key downstream target G protein-coupled receptor (LGR)4 pathway discover regulatory for loss promoting leukemia-initiating...
Abstract Acute Myeloid Leukemia (AML) remains a challenging hematologic malignancy with poor prognosis due to the persistence of therapy-resistant leukemic stem cells (LSCs). Current therapeutic strategies often fail completely eradicate LSCs, leading relapse. One promising target is protease-activated receptor 1 (PAR1), G-protein-coupled selectively expressed in LSCs. Our research investigates potential targeting PAR1 eliminate LSCs and improve treatment outcomes AML. High expression cohort...
Adrenocortical carcinoma (ACC) has high recurrence rates and poor prognosis with limited response to conventional cancer therapy. Recent contributions of high-throughput transcriptomic profiling identified microRNA-497 (miR-497) as significantly underexpressed, while lncRNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) overexpressed in ACC. miR-497 is located the chromosomal region 17p13.1, which there a frequency loss heterozygosity We aim investigate interaction ACC its...
Patient-derived xenografts (PDXs) are the most valuable tool for preclinical drug testing because they retain genetic diversity and phenotypic heterogeneity of original tumor. Acute myeloid leukemia (AML) remains difficult to engraft in immunodeficient mice. This is particularly true long-term frozen patient specimens. protocol designed establish PDXs human AML with improved engraftment rates. The optimized approach increases viability cells before implantation, efficiently monitors vivo...
Adrenocortical carcinoma (ACC) has poor outcomes and there is a need for novel effective treatments metastatic disease adjuvant therapy. miRNAs are small endogenous noncoding RNAs that control gene expression. dysregulated in all cancers manipulation of miRNA levels under investigation as therapy other with such mesothelioma. In this review, the rationale will be presented along current understanding role dysregulation regulation ACC. Potential therapeutic approaches using established...
Abstract Acute myeloid leukemia (AML) is an aggressive blood cancer with limited therapeutic options against leukemic stem cells (LSCs), resulting in poor clinical outcomes for decades. We have demonstrated the importance of aberrant activation RSPO3/β-catenin pathway a subset prognosis AML (Cancer Cell, 38:263-278, 2020) and its ability to sustain low levels reactive oxygen species (ROS), critical characteristic human LSCs. This current study has extended our recent finding, first time...